Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 11/20 | 0.53 |
| ▸ | HTR1A | P08908 | 10/20 | 0.53 |
| ▸ | HTR2B | P41595 | 10/20 | 0.53 |
| ▸ | HTR3A | P46098 | 9/20 | 0.53 |
| ▸ | HTR6 | P50406 | 8/20 | 0.53 |
| ▸ | NCF1 | P14598 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 2/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769533 | 0.95 | HTR6 (0.49) | HTR7HTR1AHTR2BHTR3AHTR6 | |
| SCHEMBL3751377 | 0.88 | NPY5R (0.41) | HTR7HTR1AHTR2BHTR3AHTR6 | |
| SCHEMBL3754790 | 0.87 | NPY5R (0.43) | NCF1 | |
| SCHEMBL3754803 | 0.79 | NCF1 (0.44) | NCF1 | |
| SCHEMBL3998045 | 0.76 | ADRB1 (0.43) | HTR7HTR1AHTR2BHTR3AHTR6 | |
| SCHEMBL3760252 | 0.74 | HTR6 (0.51) | HTR7HTR1AHTR2BHTR3AHTR6 | |
| SCHEMBL3756490 | 0.72 | SIGMAR1 (0.47) | — | |
| SCHEMBL3752036 | 0.71 | HTR1A (0.41) | HTR7HTR1AHTR2BHTR3AHTR6 | |
| SCHEMBL409069 | 0.69 | ADRB1 (0.86) | HTR7HTR1AHTR2BHTR3AHTR6 | |
| SCHEMBL3996914 | 0.68 | SRD5A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2029570-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | HTR7 2294/4885HTR1A 3013/4885HTR2B 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.